Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients
| Autor: | Mingzhang Zhao, Jun Cui, Zengwang Zhang, Hao Zhang, Bin He |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Concordance Disease Urine Disease-Free Survival Circulating Tumor DNA 03 medical and health sciences T790M chemistry.chemical_compound 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Genetics medicine Biomarkers Tumor Humans Lung cancer Protein Kinase Inhibitors Survival analysis Aged Neoplasm Staging business.industry General Medicine Middle Aged medicine.disease Prognosis ErbB Receptors 030104 developmental biology chemistry Egfr mutation 030220 oncology & carcinogenesis Mutation Female business DNA |
| Zdroj: | Cancer biomarkers : section A of Disease markers. 23(3) |
| ISSN: | 1875-8592 |
| Popis: | Purpose The need for less invasive procedures for lung cancer probing is critically needed to better understand the disease. The purpose of the current study aims to explore the use of circulating tumor DNA (ctDNA) derived from plasma and urine specimens. Methods Matched peripheral blood and morning urine specimens were obtained from 160 late stage NSCLC patients. The amount of ctDNA was quantified for each of the patients. Activating and sensitizing EGFR mutations commonly found in NSCLC patients were profiled. Longitudinal analysis was performed to compared DNA variations during disease progression. Results Measurement of EGFR mutations in NSCLC patients using plasma and urinal DNA demonstrated strong concordance to conventional tissue biopsy profiling. Baseline matched tumor samples yielded 82.8% and 84.0% for plasma and urinal DNA respectively. For these measurements, the positive predictive value was 100% for plasma and urinal DNA. In the longitudinal study, we observed strong links to disease severity and survival analysis showed a clear trend with patients having higher DNA concentrations to have worse outcome especially for urinal DNA. HR for patients stratified using plasma and urinal DNA were 1.23 and 2.55 respectively. Conclusion Measurements of circulating DNA within body fluids presented potentially new tools for the disease management of NSCLC patients with EGFR mutations. We demonstrated both plasma and urinal DNA correlated well to tissue biopsies and were potentially prognostic to address patients' survival outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |